http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2392915-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
filingDate 2000-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cc82ae177224c829f5d697af3e1cdf2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c73af27debe2e9c3fb92fb7adb1eee4d
publicationDate 2004-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GB-2392915-A
titleOfInvention Pharmaceutical formulation of fluticasone propionate
abstract A pharmaceutical aerosol formulation which comprises <SL> <LI>(i) fluticasone propionate at a concentration of 0.025 to 0.04% w/v; <LI>(ii) 1, 1, 1, 2-tetrafluoroethane (HFA 134a) as propellant; and <LI>(iii) ethanol; characterised in that the fluticasone propionate is completely dissolved in the formulation and characterised in that the formulation contains fluticasone propionate as the only medicament. The formualation may further contain a low volatility component such as glycerol. Also shown is a canister and a metered dose inhaler containing the aerosol formulation. </SL>
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9114164-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10959965-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10258568-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10258569-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10039828-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10668018-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11559505-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11559506-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9517216-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11559507-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012156711-A1
priorityDate 1999-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0048587-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9632151-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1084726-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62551
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419522605
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87113599
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8020
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419499062
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506142
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449262584
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546554
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67940
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13129
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID17897881
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453704699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483452
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311101
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444036
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID753
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545382
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419572524
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416290180

Total number of triples: 50.